2871 related articles for article (PubMed ID: 21668311)
1. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
5. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
[TBL] [Abstract][Full Text] [Related]
6. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
7. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
Karan D
Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
[TBL] [Abstract][Full Text] [Related]
8. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
9. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
[TBL] [Abstract][Full Text] [Related]
10. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
11. Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.
Dong L; Zhang X; Ren J; Wu S; Yu T; Hou L; Fu L; Yi S; Yu C
Cancer Biother Radiopharm; 2013 Jun; 28(5):391-7. PubMed ID: 23701419
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
14. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
Kim JJ; Trivedi NN; Wilson DM; Mahalingam S; Morrison L; Tsai A; Chattergoon MA; Dang K; Patel M; Ahn L; Boyer JD; Chalian AA; Schoemaker H; Kieber-Emmons T; Agadjanyan MA; Weiner DB
Oncogene; 1998 Dec; 17(24):3125-35. PubMed ID: 9872328
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
18. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
19. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
Mai TJ; Ma R; Li Z; Bi SC
Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
[TBL] [Abstract][Full Text] [Related]
20. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]